Hypoxic sensitizer and cytotoxin for head and neck cancer

Annals of the Academy of Medicine Singapore

Volumn 25, Issue 3, 1996, Pages 397-404

  Lee, D J ^a,b   Moini, M ^a   Giuliano, J ^a   Westra, W H ^b  

^a Oncology Center   (United States)

^b JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

etanidazole; radiosensitizer; tirapazamine; tumour hypoxia

Indexed keywords

ANTINEOPLASTIC AGENT; ETANIDAZOLE; MISONIDAZOLE; NIMORAZOLE; RADIOSENSITIZING AGENT; TIRAPAZAMINE;

CLINICAL TRIAL; HEAD AND NECK CANCER; HUMAN; HYPOXIA; RADIOSENSITIZATION; REVIEW; SURVIVAL;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA; CELL HYPOXIA; CLINICAL TRIALS; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; ETANIDAZOLE; HEAD AND NECK NEOPLASMS; HUMANS; HYPERBARIC OXYGENATION; MICE; MICROELECTRODES; MISONIDAZOLE; OXYGEN CONSUMPTION; RADIATION TOLERANCE; RADIATION-SENSITIZING AGENTS; SURVIVAL RATE; TREATMENT OUTCOME; TRIAZINES;

EID: 0029789354     PISSN: 03044602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (42)

1. Gray L H, Conger A D, Ebert M, Hornsey S, Scott O C A. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol 1953; 26:638-48.
2. Thomlinson R H, Gray L H. The histological structure of some human lung cancers and the possible implications for radiotherapy. Br J Cancer 1955, 9:539-49
3. Brown J M. Evidence for acutely hypoxic cells in mouse tumours, and a possible mechanism of reoxygenation. Br J Radiol 1979; 52.650-6.
4. Chaplin D J, Durand R E, Olive P Acute hypoxia in tumours: Implications for modifiers of radiation effects. Int J Radiat Oncol Biol Phys 1986, 12 1279-82.
5. Vaupel P W, Frinak S, Bicher H. Heterogeneous oxygen partial pressure and pH distribution in C3H mouse mammary adenocarcinoma Cancer Res 1981; 41 2008-13.
6. Gatenby R A, Kessler H B, Rosenblum J S, Cola L R, Moldofsky P J, Hartz W H, et al. Oxygen distribution in squamous cell carcinoma metastasis and its relationship to outcome of radiation therapy. Int J Radiat Oncol Biol Phys 1988, 14:831-8
7. Terris D J, Minchmton A I, Dunphy E P, Brown J M. Computerized histographic oxygen tension measurements of murine tumours. In: Erdmann W, Bruley D F, editors Oxygen Transport to Tissue XIV. New York, NY: Plenum Press, 1992:153-9.
8. Terris D J, Dunphy E P Oxygen tension measurements of head and neck cancers Arch Otolaryngol Head Neck Surg 1994, 120:283-7.
9. Koh W J, Raysey J S, Evans M L, Grierson J R, Lewellen T K, Graham G R, et al. Imaging of human tumour hypoxia with [F-18] fluoromisonidazole. Int J Radiat Oncol Biol Phys 1992; 22 199-212
10. Groshar D, McEwan A J, Parliament M B, Urtasun R C, Goldberg L E, Hoskinson M, et al. Imaging tumour hypoxia and tumour perfusion J Nucl Med 1993; 34:885-8.
11. Bhujwalla Z M, Shungu D C, He Q, Wehrle J P, Glickson J D MR studies of tumour: Relationship between blood flow, metabolism and physiology In Gillies R J, editor. MRI in Physiology and Biomedicine. San Diego, CA. Academic Press, 1994 311-28.
12. Blitzer P H, Wang C C, Suit H D. Blood pressure and hemoglobin concentration: multiple variate analysis of local control after irradiation for head and neck cancer. Int J Radiat Oncol Biol Phys 1984; 10(suppl 2):98.
13. Overgaard J, Hansen H S, Jorgensen K, Hansen M H. Primary radiotherapy of larynx and pharynx carcinoma: An analysis of some factors influencing local control and survival. Int J Radiat Oncol Biol Phys 1985; 12:515-21.
14. Overgaard J, Hansen H S, Anderson A P, Hjelm-Hensen M, Jorgensen K, Sandberg E, et al. Misonidazole combined with split course radiotherapy in the treatment of invasive carcinoma of larynx and pharynx, report from the DAHANCA study. Int J Radiat Oncol Biol Phys 1989; 16:1065-8.
15. Fazekas J T, Scott C, Marcial V, Davis L W, Wasserman T, Cooper J S. The role of hemoglobin concentration in the outcome of misonidazole-sensitized radiotherapy of head and neck cancers: based on RTOG trial #79-15. Int J Radiat Oncol Biol Phys 1989; 17:1177-81.
16. Henk J M, Kunkler P B, Smith C W. Radiotherapy and hyperbaric oxygen in head and neck cancer. Final report of first controlled clinical trial. Lancet 1977; ii:101-3.
17. Henk J M, Smith C W. Radiotherapy and hyperbaric oxygen in head and neck cancer. Interim report of second clinical trial. Lancet 1977; ii:104-5.
18. Adams G E, Clark E D, Flockart I R, Jacobs R S, Sehmi D S, Straford I J, et al. Structure-activity relationships in the development of hypoxic cell sensitizers: I. Sensitization efficiency. J Radiat Biol 1979; 35 133-50.
19. Adams G E, Clark E D, Gray P, Jacobs R S, Straford I J, Wardam P, et al. Structure-activity relationships in the development of hypoxic cell sensitizers: II. Cytotoxicity and therapeutic ratio. Int J Radiat Biol 1979; 35:151-60.
20. Hall E Radiosensitizers and bioreductive drugs. In: Hall E, editor. Radiobiology for the Radiologist. 4th ed. Philadelphia, PA: Lippencott Co, 1994:165-78.
21. Coleman C N. Hypoxic cell radiosensitizer expectations and progress in drug development Int J Radiat Oncol Biol Phys 1985; 11:232-9.
22. Overgaard J. Sensitization of hypoxic tumour cells. Clinical experience. Int J Radiat Biol 1989; 56:801-11.
23. Phillips T, Wasserman T H, Stetz J, Brady L. Clinical trials of hypoxic cell sensitizers. Int J Radiat Oncol Biol Phys 1982; 8:327-34.
24. Fazekas J T, Pajak T F, Wasserman T, Marcial V A, Davis L W, Kramer S, et al. Failure of misonidazole-sensitized radiotherapy to impact upon outcome among stage III-IV squamous cancers of the head and neck. Int J Radiat Oncol Biol Phys 1987; 13:1155-60.
25. Van den Bogaert W, Van der Schueren E, Hoirot J C, De Vilhena M, Schraub S, Svoboda V, et al. The EORTC randomized trial on three fractions per day and misonidazole (trial no. 22811) in advanced head and neck cancer: long term results and side effects. Radiother Oncol 1995; 35:91-9.
26. Overgaard J, Hansen HS, Lindelov B, Overgaard M, Jorgenson K, Rusmusson B Nimorazole as a hypoxic radiosensitizer in the treatment of supraglottic larynx and pharyngeal carcinoma. First report from the Danish Head and Neck Cancer Study (DAHANCA) protocol 5-85. Radiother Oncol 1991; 20 [suppl]:143-9.
27. Overgaard J, Overgaard M, Nielsen O S, Pedersen A K, Timonthy A R. A comparative investigation of nimorazole and misonidazole as hypoxic radiosensitizers in a C3H mammary carcinoma in vivo. Br J Cancer 1982; 46:904-11.
28. Brown J M, Yu N Y, Brown D N, Lee W W. SR-2508 A 2-nitro-imidazole amide which should be superior to misonidazole as a radiosensitizer for clinical use. Int J Radiat Oncol Biol Phys 1981; 7:695-703
29. Coleman C N, Halsey R S, Cox R S, Hirst V, Blaschke T, Howes A, et al Relationship between the neurotoxicity of the hypoxic cell radiosensitizer SR 2508 and the pharmacokinetic profile. Cancer Res 1987; 47:319-22.
30. Coleman C N, Wasserman T H, Urtasun R C, Halsey J, Hirst V K, Hancock S, et al. Phase I trial of the hypoxic cell radiosensitizer SR 2508: the results of the five to six week drug schedule. Int J Radiat Oncol Biol Phys 1986; 12:1105-8.
31. Lee D J, Cosmatos D, Marcial V A, Fu K K, Rotman M, Cooper J S, et al Results of an RTOG phase III trial (RTOG 85-27) comparing radiotherapy plus etanidazole with radiotherapy alone for locally advanced head and neck carcinomas. Int J Radiat Oncol Biol Phys 1995; 32:567-76.
32. Chassagne D, Charreau I, Sancho-Garnier H, Eschwege F, Malaise E P. First analysis on tumour regression for the European randomized trial of etanidazole combined with radiotherapy in head and neck carcinomas. Int J Radiat Oncol Biol Phys 1992, 22:581-4.
33. Overgaard J. Clinical evaluation of nitroimidazoles as modifiers of hypoxia in solid tumours. Oncol Res 1994; 6:509-18.
34. Brown J M, Zeman E M, Baker M A, Lemmon M J, Hirst V K, Stone H B. SR 4233: a new anticancer drug which generates cytotoxic free radicals selectively in solid tumours. In: Hyaishi O, editor Medical, Biochemical, and Chemical Aspects of Free Radicals: Proceedings of the 4th Biennial General Meeting of the Society for Free Radical Research, 1988 April 9-13, Kyoto, Japan. NY: Elsevier, 1989.1477-84.
35. Brown J M. SR 4233 (Tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours. Br J Cancer 1993; 67:1163-70.
36. Workman P. Key note address: Bioreductive mechanisms. Int J Radiat Oncol Biol Phys 1992; 22.631-7.
37. Brown J M. Clinical trials of radiosensitizers: What should we expect? Int J Radiat Oncol Biol Phys 1984; 10:425-9.
38. Brown J M, Lemmon M J. Potentiation by hypoxic cytotoxin SR 4233 of cell killing produced by fractionated irradiation of mouse tumours. Cancer Res 1990; 50:7745-9.
39. Doherry N, Hancock S L, Kaye S, Coleman S N, Shulman L, Marquez C, et al. Muscle cramping in phase I clinical trials of tirapazamine (SR 4233) with and without radiation. Int J Radiat Oncol Biol Phys 1994; 29.379-82.
40. Brown J M. Hypoxic cell radiosensitization: the end of an era? Regarding Lee et al [editorial]. Int J Radiat Oncol Biol Phys 1995, 32:883-5.
41. Griffin T W, Pajak T F, Gillespie B W, Davis L W, Brady L W, Rubin P, et al. Predicting the response of head and neck cancers to radiotherapy with a multivariate modelling system: An analysis of the RTOG head and neck tumour registry. Int J Radiat Oncol Biol Phys 1984; 10:481-7.
42. Bogaert W V D, Schueren E V D, Horiot J C, Vilhena M D, Schraub S, Svoboda V, et al. The EORTC randomized trial on three fractions per day and misonidazole in advanced head and neck cancer: prognostic factors. Radiother Oncol 1995; 35:100-6.